Background Oncological therapies can cause a variety of mucocutaneous adverse events.
Exanthematous adverse events can be challenging in the context of the urgent need for …

Given the increasing use of novel targeted therapies, dermatologists are constantly
confronted with novel cutaneous side effects of these agents. A rapid diagnosis and …

Immune checkpoint inhibitors are a new class of oncologic drugs that act via the inhibition of
checkpoints, thereby unlocking the immune system to attack cancer cells. Their emergence …

Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), drug
reactions with eosinophilia and systemic symptoms (DRESS) have been very rarely …

Introduction Novel anti-cancer drugs such as targeted cancer therapies and immune check-
point inhibitors (ICIs) have adverse events, especially concerning the skin. The aim of this …

As treatment with immune checkpoint inhibitors (CPIs) for cancer increases, so has the
incidence of immune-related cutaneous adverse events (irCAEs). These toxicities can …

Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have become a mainstay of
oncologic treatment over the past decade. There are currently 11 ICIs approved by the US …

The introduction of immune checkpoint inhibitors as a treatment modality in advanced
malignancies has revolutionized the field of oncology therapeutics. Immunotherapy …

The introduction of immune checkpoint inhibitors (ICIs) has transformed the management of
various malignancies. Alongside their therapeutic success, the widespread application of …

This chapter focuses on the broad side effect profile that can impact the skin in cancer
patients treated with checkpoint inhibitors. Special features include the clinical …